Spectrum Pharmaceuticals has completed enrollment for a Phase II trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma. The trial will evaluate safety and efficacy in 60 patients. The primary objective of the study is to determine the overall safety and toxicity profile in multiple myeloma patients receiving 200 mg/m2 of Melphalan HCl for Injection (Propylene Glycol-Free) as my...